Spectral AI Inc Dossier - Source-backed chat

Spectral AI Inc

MDAINASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.12

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.66Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $53.4M

Enterprise Value $51.3M

Shares Outstanding 34M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Spectral AI, Inc. (NASDAQ: MDAI) is transitioning from a late-stage development entity to a commercial-stage medical diagnostics company following the landmark FDA De Novo Classification of its DeepView System for burn wound assessment in May 2026. Backed by substantial non-dilutive government funding (primarily from BARDA), the company possesses a robust balance sheet and a highly differentiated AI-driven platform. While near-term financials reflect typical pre-commercialization losses, the removal of regulatory hurdles in the US and the expected launch of commercial sales by late 2026 position the stock for significant long-term upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$5.13

High · most bullish analyst$6.25

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

Commercial adoption of the DeepView System is slower than expected due to hospital procurement delays, reimbursement challenges, or intense competition from established wound care giants. Cash burn increases, forcing the company to seek dilutive equity financing despite existing BARDA support.

Base CaseCentral scenario

$4.6750%

Spectral AI successfully executes its initial commercial launch in late 2026, meeting its FY2026 revenue guidance of $18.5 million (primarily driven by BARDA contract development work). Commercial sales begin to scale gradually in 2027, supported by the $31.7 million in advanced BARDA funding, aligning with the consensus analyst price target.

Bull CaseUpside scenario

$6.2530%

Rapid commercial adoption of the DeepView System in US burn centers and emergency departments, coupled with accelerated international expansion (UK, Australia, GCC) and successful development of the handheld device, drives exponential revenue growth. The company secures high-margin recurring licensing fees, achieving profitability ahead of consensus expectations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA De Novo Classification granted in May 2026 for the DeepView System (burn indication), removing the primary regulatory hurdle.
Substantial non-dilutive funding with $31.7 million in advanced BARDA funding to support accelerated development.
First-of-its-kind predictive AI diagnostic platform built on over 340 billion pixels of clinical wound data.
Clear path to commercialization with initial sales expected by year-end 2026.

Key Investment Risks

Execution risk associated with transitioning from a development-stage entity to a commercial sales model.
Dependence on government contracts (primarily BARDA) for the majority of current revenues.
Potential hospital procurement delays and complex reimbursement landscapes for new medical devices.
Ongoing cash burn ($3.7 million in Q1 2026) which could necessitate future capital raises if commercial sales lag.

Thesis Invalidation Triggers

Failure to generate initial commercial sales of the DeepView System by the end of 2026.
Significant delays or negative feedback regarding the handheld DeepView device prototype.
A material reduction or cancellation of funding under the BARDA PBS Contract.
Inability to secure favorable reimbursement codes or clinical adoption from major hospital networks.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.